Go Pro
→ The end may be near for these iconic stocks (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:RVPH

Reviva Pharmaceuticals Q2 2025 Earnings Report

Reviva Pharmaceuticals logo
$0.48 0.00 (0.00%)
As of 02:58 PM Eastern
ProfileEarnings HistoryForecast

Reviva Pharmaceuticals EPS Results

Actual EPS
-$2.40
Consensus EPS
-$3.00
Beat/Miss
Beat by +$0.60
One Year Ago EPS
N/A

Reviva Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Reviva Pharmaceuticals Announcement Details

Quarter
Q2 2025
Date
8/14/2025
Time
Before Market Opens
Conference Call Date
Thursday, August 14, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Reviva Pharmaceuticals' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 13, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Reviva Pharmaceuticals' Q2 2025 Press ReleasePress Release
(8-K)
Reviva Pharmaceuticals' Q2 2025 Quarterly reportQuarterly report
(10-Q)

Reviva Pharmaceuticals Earnings Headlines

RVPH: Patent Filed for New Formulation
August 17, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/rvph-patent-filed-for-new-formulation-165800148.html
Reviva Pharmaceuticals: Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 13, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-08/69299534-reviva-pharmaceuticals-reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlights-399.htm
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.tc pixel
September 15 at 1:00 AM  |  Base Camp Trading (Ad)
Reviva Pharmaceuticals Files U.S. Patent Application for New Brilaroxazine Formulation, Expects FDA Feedback in Q4 2026
August 12, 2026  |  quiverquant.comQ
Reviva Reports Second Quarter 2026 Financial Results and Recent Business Highlights
August 12, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/12/3344112/0/en/reviva-reports-second-quarter-2026-financial-results-and-recent-business-highlights.html
Reviva Pharmaceuticals to Present at the Life Sciences Investor Forum on June 24th
June 23, 2026  |  financialpost.comF
See More Reviva Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Reviva Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Reviva Pharmaceuticals and other key companies, straight to your email.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals (NASDAQ:RVPH), Inc. (NASDAQ: RVPH) is a specialty pharmaceutical company focused on the acquisition, development and commercialization of prescription drug products in the United States and select international markets. Founded in 2002 and headquartered in Coral Gables, Florida, Reviva targets under-promoted, off-patent pharmaceuticals for which novel dosage forms can enhance patient compliance and therapeutic outcomes.

The company’s core activities include the identification of FDA-approved drug candidates, formulation development to address niche or underserved patient populations—such as pediatric and orphan indications—and supporting regulatory filings. Reviva maintains a lean operating model, leveraging partnerships with contract development and manufacturing organizations (CDMOs) to accelerate product development and optimize market entry.

Reviva’s current offerings span oral, injectable and topical dosage forms across therapeutic areas including metabolic disorders, dermatology and ophthalmology. In addition to its marketed portfolio, the company is advancing reformulation projects designed to improve delivery profiles, simplify dosing regimens and extend product lifecycles for previously approved drugs.

Led by Chief Executive Officer Mark C. Capparelli, Reviva’s management team combines expertise in pharmaceutical development, regulatory strategy and commercialization. The company serves markets throughout North America and works with specialty distributors in select regions to ensure broad patient access to its branded and licensed products.

View Reviva Pharmaceuticals Profile
Earnings Tools